<p>保德信金融公司在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在 Haemonetics Corporation（纽约证券交易所代码：HAE - 免费报告）的持股降低了 73.6%。该基金在季度内出售了 21,398 股后，持有 7,689 股这家医疗器械供应商的股票。截至其最近向证券交易委员会提交的文件，保德信金融公司在 Haemonetics 的持股价值为 574,000 美元。</p>
<p>其他大型投资者最近也对该公司的持仓进行了调整。Quarry LP 在第一季度将其在 Haemonetics 的股份增加了 63.4%。Quarry LP 现在拥有 495 股这家医疗器械供应商的股票，价值 31,000 美元，此前在该期间又购买了 192 股。GAMMA Investing LLC 在第二季度将其在 Haemonetics 的持股提高了 59.4%。GAMMA Investing LLC 现在拥有 443 股这家医疗器械供应商的股票，价值 33,000 美元，此前在上个季度又收购了 165 股。UMB Bank n.a.在第二季度将其在 Haemonetics 的股份增加了 91.7%。UMB Bank n.a.现在拥有 669 股这家医疗器械供应商的股票，价值 50,000 美元，此前又购买了 320 股。Parkside Financial Bank &amp; Trust 在第二季度将其在 Haemonetics 的持股增长了 11.6%。Parkside Financial Bank &amp; Trust 现在拥有 1,461 股这家医疗器械供应商的股票，价值 109,000 美元，此前又购买了 152 股。最后，Nisa Investment Advisors LLC 在第二季度将其在 Haemonetics 的持股增加了 85.4%。Nisa Investment Advisors LLC 现在拥有 1,470 股这家医疗器械供应商的股票，价值 110,000 美元，此前又购买了 677 股。目前 99.67% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>多家研究分析师最近对 HAE 股票发表了评论。BTIG Research 在 11 月 21 日的报告中重申了对 Haemonetics 的 “买入” 评级，并设定了 88.00 美元的目标价。花旗集团在 10 月 7 日的研究报告中将 Haemonetics 的目标价从 78.00 美元下调至 64.00 美元，并对该公司设定了 “买入” 评级。Weiss Ratings 在周一的研究报告中重申了对 Haemonetics 的 “持有（c-）” 评级。Raymond James Financial 在 11 月 14 日的研究报告中重申了对 Haemonetics 的 “跑赢大盘” 评级，并设定了 90.00 美元的目标价。最后，Wall Street Zen 在周六的研究报告中将 Haemonetics 的评级从 “持有” 上调至 “买入”。一位股票研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 79.70 美元。</p>
<p><strong>获取我们关于 Haemonetics 的最新报告</strong></p>
<h2>Haemonetics 股票上涨 0.7%</h2>
<p>HAE 股票在周三开盘价为 83.83 美元。该股票的 50 日移动平均价格为 63.24 美元，200 日移动平均价格为 64.03 美元。Haemonetics Corporation 的 1 年最低价为 47.31 美元，1 年最高价为 85.48 美元。该公司的市值为 39.2 亿美元，市盈率为 24.51，市盈率增长比率为 1.49，贝塔值为 0.30。该公司的债务与股本比率为 1.08，流动比率为 1.64，速动比率为 1.03。</p>
<p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）最近于 11 月 6 日发布了其财报。这家医疗器械供应商报告本季度每股收益为 1.27 美元，超出市场共识预期的 1.12 美元，超出幅度为 0.15 美元。Haemonetics 的净利润率为 12.67%，股本回报率为 27.22%。该公司本季度的收入为 3.2732 亿美元，而市场共识预期为 3.1161 亿美元。在去年同期，该公司每股收益为 1.12 美元。与去年同期相比，Haemonetics 的收入下降了 5.3%。Haemonetics 已将其 2026 财年的指引设定为 4.800-5.00 每股收益。研究分析师预计 Haemonetics Corporation 在当前财年将发布 4.55 美元的每股收益。</p>
<h2>Haemonetics 公司简介</h2>
<p>（免费报告）</p>
<p>Haemonetics Corporation 是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关耗材和解决方案，以及为血浆客户管理其捐赠者、运营和供应链的集成信息技术平台；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票而非 Haemonetics</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>如何投资蓝筹股</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆发</li>
<li>纳斯达克股票交易所是什么？</li>
<li>安海斯 - 布希收购 BeatBox 以吸引年轻饮酒者</li>
</ul>
<p><strong>想看看其他对 HAE 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Haemonetics Corporation（纽约证券交易所代码：HAE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Haemonetics 吗？</h2>
<p>在考虑 Haemonetics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Haemonetics 并不在名单上。</p>
<p>虽然 Haemonetics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

保德信金融

<p>保德信金融公司在第二季度减少了对海蒙尼克斯公司的持股，减幅为 73.6%，目前持有 7,689 股，价值 574,000 美元。其他投资者调整了他们的持仓，Quarry LP、GAMMA Investing LLC、UMB Bank n.a.、Parkside Financial Bank & Trust 以及 Nisa Investment Advisors LLC 均增加了他们的股份。分析师对海蒙尼克斯的评级不一，普遍目标价为 79.70 美元。海蒙尼克斯报告第二季度每股收益为 1.27 美元，超出预期，但营收同比下降了 5.3%</p>

<p>Prudential Financial Inc. lowered its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 73.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 7,689 shares of the medical instruments supplier's stock after selling 21,398 shares during the quarter. Prudential Financial Inc.'s holdings in Haemonetics were worth $574,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>保德信金融公司在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在 Haemonetics Corporation（纽约证券交易所代码：HAE - 免费报告）的持股降低了 73.6%。该基金在季度内出售了 21,398 股后，持有 7,689 股这家医疗器械供应商的股票。截至其最近向证券交易委员会提交的文件，保德信金融公司在 Haemonetics 的持股价值为 574,000 美元。</p>
</div><p>Other large investors have also recently made changes to their positions in the company. Quarry LP boosted its stake in Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after acquiring an additional 165 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 320 shares during the period. Parkside Financial Bank &amp; Trust grew its holdings in Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank &amp; Trust now owns 1,461 shares of the medical instruments supplier's stock valued at $109,000 after purchasing an additional 152 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Haemonetics by 85.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,470 shares of the medical instruments supplier's stock valued at $110,000 after purchasing an additional 677 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持仓进行了调整。Quarry LP 在第一季度将其在 Haemonetics 的股份增加了 63.4%。Quarry LP 现在拥有 495 股这家医疗器械供应商的股票，价值 31,000 美元，此前在该期间又购买了 192 股。GAMMA Investing LLC 在第二季度将其在 Haemonetics 的持股提高了 59.4%。GAMMA Investing LLC 现在拥有 443 股这家医疗器械供应商的股票，价值 33,000 美元，此前在上个季度又收购了 165 股。UMB Bank n.a.在第二季度将其在 Haemonetics 的股份增加了 91.7%。UMB Bank n.a.现在拥有 669 股这家医疗器械供应商的股票，价值 50,000 美元，此前又购买了 320 股。Parkside Financial Bank &amp; Trust 在第二季度将其在 Haemonetics 的持股增长了 11.6%。Parkside Financial Bank &amp; Trust 现在拥有 1,461 股这家医疗器械供应商的股票，价值 109,000 美元，此前又购买了 152 股。最后，Nisa Investment Advisors LLC 在第二季度将其在 Haemonetics 的持股增加了 85.4%。Nisa Investment Advisors LLC 现在拥有 1,470 股这家医疗器械供应商的股票，价值 110,000 美元，此前又购买了 677 股。目前 99.67% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts have recently commented on HAE shares. BTIG Research restated a &#34;buy&#34; rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Citigroup lowered their price objective on shares of Haemonetics from $78.00 to $64.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, October 7th. Weiss Ratings restated a &#34;hold (c-)&#34; rating on shares of Haemonetics in a research note on Monday. Raymond James Financial reaffirmed an &#34;outperform&#34; rating and set a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. Finally, Wall Street Zen raised Haemonetics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $79.70.</p>
<div class="lb-trans"><p>多家研究分析师最近对 HAE 股票发表了评论。BTIG Research 在 11 月 21 日的报告中重申了对 Haemonetics 的 “买入” 评级，并设定了 88.00 美元的目标价。花旗集团在 10 月 7 日的研究报告中将 Haemonetics 的目标价从 78.00 美元下调至 64.00 美元，并对该公司设定了 “买入” 评级。Weiss Ratings 在周一的研究报告中重申了对 Haemonetics 的 “持有（c-）” 评级。Raymond James Financial 在 11 月 14 日的研究报告中重申了对 Haemonetics 的 “跑赢大盘” 评级，并设定了 90.00 美元的目标价。最后，Wall Street Zen 在周六的研究报告中将 Haemonetics 的评级从 “持有” 上调至 “买入”。一位股票研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 79.70 美元。</p>
</div><p><strong>Get Our Latest Report on Haemonetics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Haemonetics 的最新报告</strong></p>
</div><h2>Haemonetics Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Haemonetics 股票上涨 0.7%</h2>
</div><p>Shares of HAE stock opened at $83.83 on Wednesday. The stock's fifty day moving average price is $63.24 and its 200 day moving average price is $64.03. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $85.48. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.</p>
<div class="lb-trans"><p>HAE 股票在周三开盘价为 83.83 美元。该股票的 50 日移动平均价格为 63.24 美元，200 日移动平均价格为 64.03 美元。Haemonetics Corporation 的 1 年最低价为 47.31 美元，1 年最高价为 85.48 美元。该公司的市值为 39.2 亿美元，市盈率为 24.51，市盈率增长比率为 1.49，贝塔值为 0.30。该公司的债务与股本比率为 1.08，流动比率为 1.64，速动比率为 1.03。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the previous year, the firm earned $1.12 EPS. Haemonetics's revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）最近于 11 月 6 日发布了其财报。这家医疗器械供应商报告本季度每股收益为 1.27 美元，超出市场共识预期的 1.12 美元，超出幅度为 0.15 美元。Haemonetics 的净利润率为 12.67%，股本回报率为 27.22%。该公司本季度的收入为 3.2732 亿美元，而市场共识预期为 3.1161 亿美元。在去年同期，该公司每股收益为 1.12 美元。与去年同期相比，Haemonetics 的收入下降了 5.3%。Haemonetics 已将其 2026 财年的指引设定为 4.800-5.00 每股收益。研究分析师预计 Haemonetics Corporation 在当前财年将发布 4.55 美元的每股收益。</p>
</div><h2>Haemonetics Company Profile</h2>
<div class="lb-trans"><h2>Haemonetics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p>
<div class="lb-trans"><p>Haemonetics Corporation 是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关耗材和解决方案，以及为血浆客户管理其捐赠者、运营和供应链的集成信息技术平台；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Haemonetics</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>如何投资蓝筹股</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆发</li>
<li>纳斯达克股票交易所是什么？</li>
<li>安海斯 - 布希收购 BeatBox 以吸引年轻饮酒者</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HAE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 HAE 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Haemonetics Corporation（纽约证券交易所代码：HAE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Haemonetics 吗？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Haemonetics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Haemonetics 并不在名单上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Haemonetics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

保德信金融公司减少了其在 Heamonetics 公司的持股 $HAE